• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Merck Announces Third-Quarter 2017 Dividend

    Merck Announces Third-Quarter 2017 Dividend

  2. FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer

    FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer

  3. FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update

    FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update

  4. Hepatitis Therapeutics Market to Reach $25.8 Billion by 2025 - Key Players are Gilead, Merck , Johnson & Johnson, Bristol-Myers Squibb Company & AbbVie - Research and Markets

    Hepatitis Therapeutics Market to Reach $25.8 Billion by 2025 - Key Players are Gilead, Merck , Johnson & Johnson, Bristol-Myers Squibb Company & AbbVie - Research and Markets

  5. Depth Filtration Market to Reach $2.96 Billion by 2022 - Key Players are Merck , Pall Corporation, Sartorius Stedim Biotech, 3M Company & Eaton Corporation - Research and Markets

    Depth Filtration Market to Reach $2.96 Billion by 2022 - Key Players are Merck , Pall Corporation, Sartorius Stedim Biotech, 3M Company & Eaton Corporation - Research and Markets

  6. FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), ...

    FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression

  7. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

  8. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

  9. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

  10. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

12345

©2017 Morningstar Advisor. All right reserved.